|
1
|
Zaidi M: Skeletal remodeling in health and
disease. Nat Med. 13:791–801. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodan GA and Martin TJ: Therapeutic
approaches to bone diseases. Science. 289:1508–1514. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suda T, Takahashi N, Udagawa N, Jimi E,
Gillespie MT and Martin TJ: Modulation of osteoclast
differentiation and function by the new members of the tumor
necrosis factor receptor and ligand families. Endocr Rev.
20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee ZH and Kim HH: Signal transduction by
receptor activator of nuclear factor kappa B in osteoclasts.
Biochem Biophys Res Commun. 305:211–214. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee
SY and Kim N: Akt induces osteoclast differentiation through
regulating the GSK3β/NFATc1 signaling cascade. J Immunol.
188:163–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faccio R and Cremasco V: PLCgamma2: Where
bone and immune cells find their common ground. Ann N Y Acad Sci.
1192:124–130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takayanagi H, Kim S, Koga T, Nishina H,
Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, et al:
Induction and activation of the transcription factor NFATc1 (NFAT2)
integrate RANKL signaling in terminal differentiation of
osteoclasts. Dev Cell. 3:889–901. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sato K, Suematsu A, Nakashima T,
Takemoto-Kimura S, Aoki K, Morishita Y, Asahara H, Ohya K,
Yamaguchi A, Takai T, et al: Regulation of osteoclast
differentiation and function by the CaMK-CREB pathway. Nat Med.
12:1410–1416. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Negishi-Koga T and Takayanagi H:
Ca2+-NFATc1 signaling is an essential axis of osteoclast
differentiation. Immunol Rev. 131:241–256. 2009. View Article : Google Scholar
|
|
11
|
Singh RK, Gupta S, Dastidar S and Ray A:
Cysteinyl leukotrienes and their receptors: Molecular and
functional characteristics. Pharmacology. 85:336–349. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nayak A: A review of montelukast in the
treatment of asthma and allergic rhinitis. Expert Opin
Pharmacother. 5:679–686. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Theron AJ, Steel HC, Tintinger GR, Gravett
CM, Anderson R and Feldman C: Cysteinyl leukotriene receptor-1
antagonists as modulators of innate immune cell function. J Immunol
Res. 2014:6089302014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hikiji H, Takato T, Shimizu T and Ishii S:
The roles of prostanoids, leukotrienes and platelet-activating
factor in bone metabolism and disease. Prog Lipid Res. 47:107–126.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Method. 25:402–208. 2001.
View Article : Google Scholar
|
|
16
|
Ishijima M, Rittling SR, Yamashita T,
Tsuji K, Kurosawa H, Nifuji A, Denhardt DT and Noda M: Enhancement
of osteoclastic bone resorption and suppression of osteoblastic
bone formation in response to reduced mechanical stress do not
occur in the absence of osteopontin. J Exp Med. 193:399–404. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Virchow JC and Bachert C: Efficacy and
safety of montelukast in adults with asthma and allergic rhinitis.
Respir Med. 100:1952–1959. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wagner EF and Karsenty G: Genetic control
of skeletal development. Curr Opin Genet Dev. 11:527–532. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wada T, Nakashima T, Hiroshi N and
Penninger JM: RANKL-RANK signaling in osteoclastogenesis and bone
disease. Trends Mol Med. 12:17–25. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ha H, Lee JH, Kim HN, Kim HM, Kwak HB, Lee
S, Kim HH and Lee ZH: alpha-Lipoic acid inhibits inflammatory bone
resorption by suppressing prostaglandin E2 synthesis. J Immunol.
176:111–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Riccioni G, Bucciarelli T, Mancini B, Di
Ilio C and D'Orazio N: Antileukotriene drugs: Clinical application,
effectiveness and safety. Curr Med Chem. 14:1966–1977. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paggiaro P and Bacci E: Montelukast in
asthma: A review of its efficacy and place in therapy. Ther Adv
Chronic Dis. 2:47–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim N, Takami M, Rho J, Josien R and Choi
Y: A novel member of the leukocyte receptor complex regulates
osteoclast differentiation. J Exp Med. 195:201–209. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koga T, Inui M, Inoue K, Kim S, Suematsu
A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, et al:
Costimulatory signals mediated by the ITAM motif cooperate with
RANKL for bone homeostasis. Nature. 428:758–763. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferron M, Boudiffa M, Arsenault M, Rached
M, Pata M, Giroux S, Elfassihi L, kisseleva M, Majerus PW, Rousseau
F and Vacher J: Inositol polyphosphate 4-phosphatase B as a
regulator of bone mass in mice and humans. Cell Metab. 14:466–477.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim H, Kim T, Jeong BC, Cho IT, Han D,
Takegahara N, Negishi-Koga T, Takayanagi H, Lee JH, Sul JY, et al:
Tmem64 modulates calcium signaling during RANKL-mediated osteoclast
differentiation. Cell Metab. 17:249–260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Capite J, Shirley A, Nelson C, Bates G
and Parekh AB: Intercellular Ca2+ wave propagation involving
positive feedback between CRAC channels and cysteinyl leukotrienes.
FASEB J. 3:894–905. 2009. View Article : Google Scholar
|
|
28
|
Tintinger GR, Feldman C, Theron AJ and
Anderson R: Montelukast: More than a cysteinyl leukotriene receptor
antagonist? Sci World J. 10:2403–2413. 2010. View Article : Google Scholar
|
|
29
|
Fredriksson R, Lagerstrom MC, Lundin LG
and Schioth HB: The G-protein-coupled receptors in the human genome
form five main families. Phylogenetic analysis, paralogon groups
and fingerprints. Mol Pharmacol. 63:1256–1272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nonaka Y, Hiramoto T and Fujita N:
Identification of endogenous surrogate ligands for human P2Y12
receptors by in silico and in vitro methods. Biochem Biophys Res
Commun. 337:281–288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Finsterer J and Frank M: Repurposed drugs
in metabolic disorders. Curr Top Med Chem. 13:2386–2394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
